Inquis Medical announced a $40 million funding round to support the completion of a pivotal trial for its Aventus thrombectomy system, with plans to launch the product in 2025. The Aventus system, which received 510(k) clearance in November 2023, is designed for the non-surgical removal of blood clots using aspiration technology. This technology is akin to that used by Inari Medical’s Flowtriever, but Inquis has introduced a unique sensing technology that informs the operator whether the device is in contact with blood, a clot, or vessel walls, aiming to enhance procedural efficiency and safety.
The pivotal trial for Aventus is enrolling 120 participants with acute pulmonary embolism to undergo aspiration thrombectomy. The study's co-primary endpoints focus on major adverse events related to the device, such as death, major bleeding, and cardiac injury, as well as changes in the right ventricle/left ventricle ratio. Inquis believes that its tissue-sensing tip, blood return system, and integrated navigation catheter set Aventus apart from existing products, which are often limited by significant blood loss and procedural inefficiencies.
Investment firm Marshall Wace led the $40 million Series B financing round, with contributions from existing backers including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. This funding will enable Inquis to advance its pivotal trial and prepare for the commercial launch of Aventus, positioning the company as a competitor in the thrombectomy device market.
